Investor Relations

AVEO Oncology is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates.

NASDAQ | AVEO (Common Stock)
$1.34 - 0.03
Stock chart for: AVEO.O.  Currently trading at $1.34 with a 52 week high of $3.50 and a 52 week low of $0.61.
09/03/15 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related AntibodiesRead More
AVEO Oncology Reports Second Quarter 2015 Financial ResultsRead More
AVEO Oncology to Host Midyear Update Conference Call on August 10, 2015Read More

Latest Event